The prognosis for patients with peritoneal carcinomatosis (PC) from gastrointestinal malignancies is dismal. Recent efforts combining aggressive cytoreduction of intraperitoneal disease with perioperative chemotherapy have demonstrated improved overall survival and quality of life in these patients. 1, 2 Among the most important prognostic factors determining survival after cytoreduction is completeness of resection. Unfortunately, the ability to identify macroscopic or microscopic residual tumor deposits at the time of cytoreductive surgery is limited, and, as such, disease recurs in the majority of patients. Methods that enhance intraoperative detection of minimal residual disease may improve completeness of cytoreduction and patient outcomes. normal cells. Their therapeutic efficacy in experimental models of gastrointestinal cancer has been demonstrated in previous publications. 4, 5 One such virus is NV1066, a genetically engineered oncolytic HSV strain that carries the transgene for marker protein, enhanced green fluorescent protein (GFP). Cancer cells infected with NV1066 constitutively express GFP, which can be detected using fluorescent imaging. Advantages of such a marker protein have been demonstrated in several in vitro experiments. The recent development in our laboratory of a fluorescent laparoscopic system, in combination with the advent of NV1066, has led to the discovery of novel applications of in vivo cancer imaging.
We evaluated the ability of NV1066-mediated cancer cell-specific expression of GFP to enhance the intraoperative detection of minimal residual disease after cytoreductive surgery using virally directed fluorescent imaging (VFI).
MATERIALS AND METHODS Cells
The human gastric cancer cell line OCUM-2MD3 and the malignant mesothelioma cell line JMN were studied. OCUM-2MD3 cells were a gift from Dr. Masakazu Yashiro (Osaka City University Medical School, Osaka, Japan) and were grown in Dulbecco's modified Eagle's medium supplemented with high glucose, 2 mmol/L L-glutamine, 0.5 mmol/L sodium pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal calf serum (FCS). JMN cells were a gift of Dr. Francis Sirotnak (Memorial Sloan-Kettering Cancer Center, New York, NY) and were grown in Roswell Park Memorial Institute 1640 media supplemented with 100 U/ mL penicillin, 100 mg/mL streptomycin, and 10% FCS. Vero cells (American Type Culture Collection, Rockville, MD) were grown in minimum essential medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% FCS. Cells were maintained in a 5% CO 2 humidified incubator at 37 C.
Virus
NV1066 is a replication-competent oncolytic HSV-1 strain whose construction has been described in detail. 6 Briefly, NV1066 was derived from the wild-type HSV-1 virus (F strain) by deletions in the viral virulence genes ICP0, ICP4, and g 1 34.5. These deletions attenuate the virus conferring selectivity for infection of cancer cells and render the virus safe for use in humans. In addition, the transgene for enhanced GFP was inserted into the deleted region under the control of a constitutively expressed cytomegalovirus promoter. Viral stocks were propagated on Vero cells and titered by standard plaque assay.
Detection of Green Fluorescent Protein Expression by Fluorescent Microscopy
Monolayer cultures of OCUM-2MD3 cells were incubated at 37 C and infected with NV1066 at a multiplicity of infection (MOI, ratio of the number of viral particles to the number of tumor cells) of 1.0. A Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss, Inc., Oberkochen, Germany) and the MetaMorph Imaging System (Downingtown, PA) were used to visualize GFP-expressing cancer cells hourly after infection. GFP expression was identified after placement of specific excitation and emission filters to detect GFP. The Retiga EX digital CCD camera (Qimaging, Burnaby, Canada) was used for image capture.
Detection of Green Fluorescent Protein Expression by Flow Cytometry
Cultured cells (5 3 10 4 ) were plated in six-well flat-bottom assay plates (Becton Dickinson, Franklin Lakes, NJ) in 2 mL of media. After overnight incubation at 37 C, cells were infected with NV1066 at MOIs of 0.01, 0.1, or 1.0 in 100 mL of phosphatebuffered saline (PBS). Untreated cells served as a negative control. Daily after infection, cells were harvested with 0.25% trypsin in 0.02% EDTA, combined with the supernatant fraction, centrifuged, washed with PBS, and resuspended in 100 mL of PBS; 5 mL of 7-amino-actinomycin (7-AAD; BD Pharmingen, San Diego, CA) was added as an exclusion dye for cell viability. Data for GFP expression from 1 3 10 4 cells were acquired on a FACS Calibur unit equipped with Cell Quest software (Becton Dickinson, San Jose, CA). Results are reported as the percentage of live cells expressing GFP. In addition, GFP-positive cells were sorted using the MoFlo High-Performance Cell Sorter (DakoCytomation, Carpinteria, CA) and stained with rabbit anti-HSV-1 polyclonal antibody (Biogenex, San Ramon, CA) to confirm viral infection of green cells. A biotinylated secondary antibody was added and visualized with streptavidin-labeled horseradish peroxidase and chromogen solutions. Each experiment was repeated a minimum of three times.
Cytotoxicity Assay
Cytotoxicity assays were performed by plating 2 3 10 4 cells in 24-well plates in 1 mL of media.
After overnight incubation at 37 C, cells were infected with NV1066 diluted in 100 mL media at MOIs of 0.01, 0.1, and 1.0. On days 3 to 7 after infection, cells were lysed with 1.35% Triton-X solution to release intracellular lactate dehydrogenase (LDH). LDH was then quantified with a Cytotox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI) that measures the conversion of a tetrazolium salt into a red formazan product. Absorbance was measured at 450 nm with a microplate reader (EL321e, Bio-Tek Instruments, Winooski, VT). Results are expressed as the surviving percentage of cells as determined by the measured absorbance of each sample relative to control, untreated cells. All samples were tested, and experiments were replicated, in triplicate.
Animal Model of Peritoneal Carcinomatosis
All animal procedures were performed under the guidelines approved by the Memorial SloanKettering Institutional Animal Care and Use Committee. Eight-to 10-week-old athymic mice (National Cancer Institute, Bethesda, MD) were housed in a temperature-and light-controlled animal facility. Food and water were permitted ad libitum. Animals were anesthetized with inhalational methoxyflurane for all experimental manipulations and were sacrificed by CO 2 inhalation at the termination of the experiment.
PC was established by injection of 1 3 10
7
OCUM-2MD3 cells suspended in 500 mL PBS into the peritoneal cavity of athymic mice (n 5 24). Twenty-one days after implantation of tumor cells, animals were treated with a single intraperitoneal injection of 1 3 10 7 plaque-forming units (PFU) of NV1066 in 100 mL of PBS (n 5 21). Three animals with PC were treated with an intraperitoneal injection of 100 mL of PBS, and three additional animals without PC were treated with a single intraperitoneal injection of 1 3 10 7 PFU of NV1066 to serve as negative controls. Forty-eight hours after viral administration, laparotomy was performed on all animals by two experienced surgeons with the intent to resect all intra-abdominal disease. Partial or complete resection of organs was performed if deemed necessary to achieve complete resection.
In Vivo Fluorescent Imaging
Immediately after resection, the peritoneal cavities of all animals were systematically examined by both bright-field and fluorescent laparoscopy. We use a laparoscopic system, developed in concert with Olympus America, Inc. (Scientific Equipment Division, Melville, NY), that images in both bright-field and fluorescent modes permitting the detection of GFP. The light source is derived from the Olympus Visera CLV-U40 model (Olympus America, Inc., Melville, NY) adapted with an interchangeable excitation filter set at 470 6 20 nm to accommodate the minor excitation peak of GFP at 475 nm and an emission filter fixed at 500 nm to accommodate the emission peak of GFP at 509 nm. The camera processor was an Olympus Visera OTV-S7V with an emission filter set at 510 nm. 6 A control button incorporated directly into the camera head enables rapid exchange between bright-field and fluorescent modes. GFP images were taken with minimal background illumination to illustrate the surrounding organs.
With this system, each mouse was individually and systematically examined by five independent, blinded observers. Each observer examined 12 predetermined anatomic areas (liver, right subdiaphragm, stomach, spleen, left subdiaphragm, intestine, mesentery, retroperitoneum, left kidney, right kidney, pelvis, and peritoneal surface) in a systematic fashion for the presence of residual disease as determined by the presence or absence of green fluorescence. These anatomic areas were designed on the peritoneal cancer index developed by Sugarbaker. 7 Investigators recorded the presence (''Yes'') or absence (''No'') of green fluorescence on a data sheet. Animals and data sheets were matched and coded with random numbers known only to a single investigator who was neither a surgeon nor an observer. Animals in which grossly evident disease remained after resection were excluded from the study. This experiment was repeated twice. Animals with disease treated by PBS and animals without disease treated by NV1066 (negative controls) were also observed in a similar fashion as described above.
Histologic Confirmation of Residual Microscopic Disease
After complete examination of each animal by all observers, intra-abdominal tissue biopsies (areas that were both green and not green) were fixed in 10% phosphate-buffered formalin and embedded in paraffin for histologic analysis. Serial 8-mm sections of all tissue blocks were cut and stained with hematoxylin-eosin (H&E) to assess for the presence of tumor. Additional slides were stained with rabbit anti-HSV-1 polyclonal antibody (Ready-to-Use, Biogenex) to detect the presence of virus in harvested tissues. A biotinylated secondary antibody was added and visualized with streptavidin-labeled horseradish peroxidase and chromogen solutions (Super Sensitive Ready-to-Use Detection System, Biogenex).
Counterstaining with Harris hematoxylin was performed.
Confirmation of Viral Specificity to Residual Microscopic Disease by Real-Time Polymerase Chain Reaction
Additional random intra-abdominal tissue samples were harvested and snap-frozen in liquid nitrogen. Genomic DNA was isolated using standard protocols (Wizard Genomic DNA Isolation Kit, Promega). Real-time quantitative polymerase chain reaction (PCR) was performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Forward (5#-ATGT TTCCCGTCTGGTCCAC-3#) and reverse (5#-C CCTGTCGCCTTACGTGAA-3#) primers and a dual-labeled fluorescent TaqMan probe (5#-FAM-CCCCGTCTCCATGTCCAGGATGG-TA MRA-3#) were designed to amplify and detect the 111-base pair fragment of the HSV immediate-early gene ICP0. Forward (5#-CGCCTACCACATCCA AGGAA-3#) and reverse (5#-GCTGGAAT TACCGCGGCT-3#) primers and a dual-labeled fluorescent TaqMan probe (5#-VIC-TGCTGGCA CCAGCTTGCCCTC-TAMRA-3#) were also designed for the 87-base pair coding sequence of 18s rRNA to normalize to the amount of total DNA present. The PCR conditions were as follows: stage 1, 50 C for 2 minutes; stage 2, 95 C for 10 minutes; stage 3 (35 cycles), 95 C for 15 seconds and 60 C for 1 minute; and stage 4, 25 C soak.
RESULTS

NV1066 Infects Cancer Cells, Expresses Green Fluorescent Protein, and Kills Cancer Cells
In vitro, NV1066 infected cancer cells, expressed GFP, and was cytotoxic to both cell lines at all MOIs (Fig. 1) . Flow cytometry for GFP was performed to demonstrate infectivity and expression of GFP in NV1066-treated OCUM-2MD3 and JMN cells ( Fig. 1, A,C ) . Six days after infection of OCUM-2MD3 cells at MOIs of 0.1 and 1.0, 100% (60%) of cells expressed GFP (P ! .01) (Fig. 1, A) . Even at a low MOI of 0.01, 86% (63%) of cells expressed GFP 6 days after infection (P ! .01). Similar results were obtained with JMN cells (Fig. 1, C ) .
To examine the oncolytic efficacy of NV1066, dose-dependent cytotoxicity assays were performed against OCUM-2MD3 and JMN cells (Fig. 1,  B,D) . NV1066 demonstrated dose-dependent cytotoxicity against both cell lines. Seven days after infection of OCUM-2MD3 cells at an MOI of 1.0, 100% (61%) of cells were killed (P ! .01) (Fig. 1, B) . At 10-fold lower MOIs of 0.1 and 0.01, 97% (61%) and 79% (64%) of cells were killed 7 days after infection, respectively (P ! .01). Similar results were seen with JMN cells (Fig. 1, D) .
Green Fluorescent Protein Can Be Detected in Infected Cancer Cells Within Hours of Infection
The GFP signal was detected as early as 4 to 6 hours after infection (Fig. 2, A) . The GFP signal intensity of infected cells was significantly higher than the autofluorescence of normal cells (230-670 logs). Immunohistochemistry for herpes viral antigen confirms the localization of GFP in HSV-infected cancer cells (Fig. 2, B,C ) . All of the green cells that were sorted by flow sorter were stained by HSV-1 antibody, confirming that the green fluorescence is indeed caused by NV1066 infection. Similarly, nongreen cells were not stained with HSV-1 antibody.
NV1066-Mediated GFP Expression Enables the Detection of Minimal Residual Disease After Complete Resection
In vivo, macroscopically undetectable tumor nodules by gross inspection and bright-field laparoscopy were readily identified by fluorescent laparoscopy because of green fluorescence. Representative images are shown in Fig. 3 .
Eight animals in which grossly evident disease remained after resection were excluded from the study. In the remaining animals, a maximum of 780 observations were possible (13 mice -9) . Table 1 shows the number of green observations for each of the 12 anatomic sites, aggregated over all mice and observers. Minimal residual disease as identified by green fluorescence was most frequently observed in the retroperitoneum, pelvis, peritoneal surface, and liver. Minimal residual disease was least commonly observed in the mesentery, stomach, and spleen. No areas of green fluorescence were identified in the negative control animals. Analysis of interobserver agreement among the five observers revealed agreement in 99% of observations.
Confirmation of Residual Microscopic Disease
Biopsies of tissues that were identified as green during fluorescent laparoscopy were confirmed to harbor tumor by routine H&E histologic analysis. Furthermore, immunohistochemical staining for herpes viral antigen demonstrated that NV1066 localized to tumor deposits in a highly specific manner. No tumor or virus was detected in non-green tissue biopsies that were analyzed. Representative sections are shown in Fig. 4 . PCR amplification of the viral gene ICP0 was used to further confirm the absence of NV1066 in non-tumor-bearing (non-green) tissues. ICP0 was not detected in any normal tissue biopsy that was analyzed, confirming the high specificity for viral infection of cancer cells, sparing normal cells (data not shown).
DISCUSSION
Peritoneal surface involvement occurs in as many as 20% to 30% of patients with gastric, colon, appendiceal, and pancreatic cancers. 8 Median survival in these patients with peritoneal disease is usually less than 1 year. 9 Moreover, recurrent bowel obstructions, malignant ascites, fistulization, and pain result in diminished quality of life.
Aggressive loco-regional treatment of these patients combining cytoreductive surgery with perioperative intraperitoneal chemotherapy aims to improve patient survival and quality of life. 8, 9 Cytoreduction entails resection of all visible tumor and stripping of all peritoneal surfaces that contain metastatic nodules. Visceral peritoneal involvement often requires concomitant resection of intraabdominal organs including the stomach, small intestine, and colorectum. In addition, perioperative intraperitoneal chemotherapy is administered to sterilize residual microscopic disease.
Such aggressive loco-regional treatment has resulted in improved survival and quality of life as reported in several publications. In one such study, Verwaal et al. 3 randomized 117 patients with PC caused by colorectal cancer to receive either standard systemic chemotherapy with or without palliative surgery, or aggressive cytoreduction combined with hyperthermic intraperitoneal chemotherapy. 3 Their reported 5-year survival of 19% exceeded historical controls, whose 5-year survival approached 0%. Similar favorable results using this approach have also been reported in patients with carcinomatosis secondary to gastric cancer, pseudomyxoma peritonei, and nongastrointestinal malignancies including peritoneal mesothelioma and sarcomatosis. 8, 10, 11 Among the most important prognostic factors after cytoreduction is completeness of resection. In the series by Verwaal et al., 3 the median survival in a subgroup of patients in whom complete cytoreduction was achieved was 42.9 months, compared with 17.4 months in patients with minimal residual disease, defined as residual macroscopic tumor < 2.5 mm after cytoreduction. 3 Similarly, the completeness of cytoreduction score developed by Sugarbaker, 7 an assessment made by the operating surgeon of the extent of residual disease after cytoreduction, has been shown to be a major prognostic indicator in patients with peritoneal surface malignancies.
The ability to detect small macroscopic residual peritoneal disease is largely limited by the lack of contrast difference between tumor nodules and surrounding normal tissues. Moreover, microscopic nodules are beyond the limits of detection of the unaided eye. Technology improving the intraoperative detection of residual peritoneal disease would facilitate complete cytoreduction and improve survival in these patients.
We demonstrate that VFI using NV1066-mediated tumor cell-specific production of GFP enhances the detection of minimal residual disease after cytoreduction in a murine model of PC. The green fluorescence emitted by NV1066 is 230 to 670 logs greater than background autofluorescence, allowing clear discrimination between tumor and normal tissues. The mean fluorescent intensity of enhanced GFP expressed by NV1066 is six-fold greater than nonenhanced GFP, and it matures four times more rapidly, reducing the lag time from infection to detection of green fluorescence. Furthermore, enhanced GFP has specific emission and excitation wavelengths (475/509 nm), eliminating autofluorescent interference. After a single intraperitoneal injection of NV1066 and presumed complete cytoreduction by two experienced surgeons, 8 of 13 mice were found to have at least one site of residual disease using VFI. In our study, residual disease was identified most commonly in the retroperitoneum, pelvis, peritoneal surface, and liver. These sites correspond to patterns of recurrence in published human series. 12, 13 In addition to providing a diagnostic benefit, the use of oncolytic herpes viruses in this setting may offer a therapeutic effect. The therapeutic efficacy of NV1066 in a murine model of PC secondary to gastric cancer has already been demonstrated by work in our laboratory.
5 Dose-dependent reduction of peritoneal weights in a murine model of PC was observed after intraperitoneal injection of NV1066. Furthermore, we have also shown that oncolytic herpes viruses interact synergistically when used in combination with chemotherapy.
14 In this study, mice with gastric carcinomatosis treated with combination viral therapy and mitomycin C had reduced tumor burdens compared with either treatment alone.
Finally, the specificity of NV1066 for cancer cells in this study further confirms observations from previous work in our laboratory. 4, 15 Immunohistologic and PCR analyses of viral presence after administration confirms specific uptake of virus in tumor tissue, sparing normal tissue. As such, expected toxicity from these agents is minimal, as demonstrated in numerous studies using NV1066 in murine models. 4, 5, 15 Furthermore, the safety of related oncolytic HSV strains in humans has been established in phase I clinical trials both from our group and others. 16, 17 
CONCLUSIONS
Promising survival benefits are being realized for patients with PC from gastrointestinal malignancies following an aggressive multimodal therapeutic approach combining cytoreductive surgery and perioperative chemotherapy. Treatment failure in these patients is frequently the result of unresected minimal residual disease. We demonstrate that VFI using NV1066-mediated tumor cell-specific production of GFP enhances the detection of minimal residual disease after cytoreduction of PC. Furthermore, NV1066 in addition to being diagnostic is therapeutic and can be combined with chemotherapy, an approach recommended in the loco-regional treatment of these patients with advanced disease.
have essentially abandoned it. The technique that they are using brilliantly uses this virus, which can infect cancer cells and then replicate in other cells; this acts as a multiplying effect, thus allowing the detection of small amounts of disease. I have three questions for the authors.
First, this targeting almost seems too good to be true to me. Is it true that this virus selectively picks up just cancer cells with no other cells next to them? If so, this may be the Holy Grail of cancer therapy. We have had a lot of Holy Grails, and I hate to jump on this bandwagon too soon. So do all different types of GI cancers express this or is this unique to this one cancer cell line?
All of the in vivo studies have looked at IP administration of this. Do you have any data looking at intravenous administration of this drug, which would make more sense clinically? It would be a way to pick up disease that isn't just on the surface of the bowel.
And third, you really just presented animal data. This seems, again, almost perfect: You have a vector that will selectively target cancer cells. Does this work in humans? Do you have the possibility to now proceed into human clinical trials?
Again, I enjoyed this very much, and thanks for asking me to discuss it.
Dr. Adusumilli: Thank you Dr. Mahvi for your kind comments and questions. With regard to your first question, about targeting of the virus specifically to cancer, we tested 110 different cancer cell lines, both human and murine, from 16 different primary organs, and this virus is able to infect and express green fluorescent protein in all the cancer cell lines. There is a difference in the sensitivity among different cancer cell lines; some are infected and expressed immediately, and others within 48 to 72 hours. One group in the laboratory is looking at targeting receptors on cancer cells. The HVEM receptors and GD receptors are very well known to be specific for herpes viruses, studied by the virologists for the last 50 years. These receptors are expressed in cancer cells, and this could be one of the reasons for the specificity. More than infection, the virus is able to replicate, exploiting the cellular metabolic rate, which is increased in the cancerous cells and cancer tissue. That may be another reason why the virus is able to survive and replicate selectively in cancer cells. Some researchers were concerned whether this virus will infect and replicate in high replicative cells such as bone marrow cells and the intestinal mucosa, and to date, both from our laboratory and from independent investigators, we did not find any evidence of replication in normal cells.
The second question is related to the route of administration. For this presentation the virus was administered intraperitoneally, and that is how we started initially, intrathoracic and intraperitoneal.
In later experiments, we were excited to notice that irrespective of the site of administration, the virus is able to travel both by hematogenous and lymphatic spread and infect specifically the cancer tissue. My colleagues, Karen Hendershott and Yun Shin Chun, both in the laboratory, are currently working on different routes of administration, not only in the cavities by systemic intravenous injection but also in a breast cancer model, injecting in the mammary fat pad and looking at the different metastases in advanced cancer. As of now, apart from intracranial route, we have tested every other route, and this virus is able to target the cancer tissue.
In response to the third question, about the applicability in human beings, as most of you know, the phase I study was completed by Dr. Fong for multiple colorectal metastases in the liver at Memorial. We subsequently went through an FDA audit successfully. The virus is proven to be safe for use in human beings. Currently, a multicenter phase II trial is about to start recruiting patients. We are also excited about pursuing the diagnostic and therapeutic uses of the HSV.
